Epidarex's gilded Lilly

Epidarex Capital expects the addition of Eli Lilly and Co. (NYSE:LLY) as an LP in the firm's early-stage VC fund will bring more than just capital. The pharma will offer drug discovery capabilities to portfolio companies and the potential for early stage partnerships.